Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KUP 101

Next Previous
Drug Profile

KUP 101

Alternative Names: KUP-101; KUP-101A

Latest Information Update: 21 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kupando
  • Class Antineoplastics; Small molecules; Vaccines
  • Mechanism of Action Toll-like receptor 4 agonists; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Infections

Most Recent Events

  • 03 Jul 2026 Kupando initiates a phase I clinical trials in Solid tumours (Late-stage disease) in Germany (IV) (NCT07600476)
  • 27 Mar 2026 Phase-I clinical trials in Solid tumours (Late-stage disease) in Germany (IV)
  • 23 Mar 2026 Preclinical trials in Infections in Germany (IV) Prior to March 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top